Biosimilar insulins: guidance for data interpretation by clinicians and users

Biosimilar insulins are approved copies of insulins outside patent protection. Advantages may include greater market competition and potential cost reduction, but clinicians and users lack a clear perspective on ‘biosimilarity’ for insulins. The manufacturing processes for biosimilar insulins are ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinemann, L., Home, P. D., Hompesch, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744724/
https://www.ncbi.nlm.nih.gov/pubmed/25974131
http://dx.doi.org/10.1111/dom.12491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744724/
https://www.ncbi.nlm.nih.gov/pubmed/25974131
http://dx.doi.org/10.1111/dom.12491

Ejemplares similares